Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
Ativan (oral, injectable), Loreev XR (1) ·
Belsomra (1) ·
Cleocin (oral, IV); Clindesse, Cleocin (vaginal); Clindets, Cleocin T (topical) (1) ·
Dayvigo (1) ·
Demadex, Soaanz (1) ·
E.E.S., EryPed, Ery-Tab, PCE, Erythrocin (lactobionate IV); topical Erygel, Akne-Mycin; ophthalmic ointment (1) ·
Keflex, Daxbia, Panixine; mostly prescribed generically (1) ·
Pen-V, Veetids (mostly generic) (1) ·
Periactin (US brand discontinued; generic widely available) (1) ·
Pyridium (Rx), Azo Standard, AZO Urinary Pain Relief (OTC) (1) ·
Quviviq (1)
classes:
Dual orexin receptor antagonist (DORA) (3) ·
narrow-spectrum)]] (1) ·
the first approved (1) ·
[[:Category:Antibacterials|Antibacterial]] (2) ·
[[:Category:Antihistamines|First-generation antihistamine]] (1) ·
[[:Category:Anxiolytics|Anxiolytic]] (1) ·
[[:Category:Azo_dyes|Azo dye]] (1) ·
[[:Category:Benzodiazepines|Benzodiazepine]] (1) ·
[[:Category:Beta-lactam_antibiotics|β-lactam antibiotic]] (2) ·
[[:Category:Cephalosporins|Cephalosporin (first-generation)]] (1) ·
[[:Category:Lincosamides|Lincosamide antibiotic]] (1) ·
[[:Category:Loop_diuretics|Loop diuretic]] (1) ·
[[:Category:Macrolide_antibiotics|Macrolide antibiotic]] (1) ·
[[:Category:Orexigenics|Appetite-promoting medicine (orexigenic)]] (1) ·
[[:Category:Penicillins|Penicillin (natural (1) ·
[[:Category:Prokinetics|Prokinetic (off-label)]] (1) ·
[[:Category:Schedule IV controlled substances|Schedule IV controlled substance]] (1) ·
[[:Category:Serotonin antagonists|Serotonin 5-HT2 antagonist]] (1) ·
[[:Category:Urinary_analgesics|Urinary tract analgesic]] (1)
mechanism:
None (7) ·
Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) ·
Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) ·
'"`UNIQ--vote-00000017-QINU`"' Anticholinergic and sedating, with the standard first-generation antihistamine Beers-list concerns in elderly patients'"`UNIQ--ref-00000018-QINU`"'. (1) ·
'"`UNIQ--vote-00000B40-QINU`"' The TRANSFORM-HF trial (2023) found no all-cause mortality difference between torsemide and furosemide in heart failure, although torsemide remains pharmacologically preferred where furosemide oral absorption is unreliable'"`UNIQ--ref-00000B41-QINU`"'. (1)
uses:
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) ·
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1) ·
Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1) ·
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"' (1) ·
'"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"' (1) ·
'"`UNIQ--vote-000004ED-QINU`"', '"`UNIQ--vote-000004EE-QINU`"', '"`UNIQ--vote-000004EF-QINU`"', '"`UNIQ--vote-000004F0-QINU`"', '"`UNIQ--vote-000004F1-QINU`"' (1) ·
'"`UNIQ--vote-00000B42-QINU`"', '"`UNIQ--vote-00000B43-QINU`"', '"`UNIQ--vote-00000B44-QINU`"', '"`UNIQ--vote-00000B45-QINU`"' (1) ·
'"`UNIQ--vote-00000D38-QINU`"', '"`UNIQ--vote-00000D39-QINU`"', '"`UNIQ--vote-00000D3A-QINU`"', '"`UNIQ--vote-00000D3B-QINU`"', '"`UNIQ--vote-00000D3C-QINU`"', '"`UNIQ--vote-00000D3D-QINU`"' (1) ·
'"`UNIQ--vote-00000E71-QINU`"', '"`UNIQ--vote-00000E72-QINU`"', '"`UNIQ--vote-00000E73-QINU`"', '"`UNIQ--vote-00000E74-QINU`"', '"`UNIQ--vote-00000E75-QINU`"' (1) ·
'"`UNIQ--vote-00000FB3-QINU`"', '''adjunctive only''' (does not treat the underlying infection) (1) ·
'"`UNIQ--vote-0000143C-QINU`"', '"`UNIQ--vote-0000143D-QINU`"', '"`UNIQ--vote-0000143E-QINU`"', '"`UNIQ--vote-0000143F-QINU`"', '"`UNIQ--vote-00001440-QINU`"', '"`UNIQ--vote-00001441-QINU`"' (1)
starting dose:
10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) ·
10-20 mg PO/IV once daily; titrate by clinical response. 1:1 IV to PO conversion (unlike furosemide's 1:2) (1) ·
100-200 mg PO TID after meals × no more than 2 days when used with concurrent antibiotic (1) ·
25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) ·
250-500 mg PO every 6-8 hours (1) ·
250-500 mg PO QID; 7.5-12.5 mg/kg IV q6h; topical and ophthalmic per formulation (1) ·
5 mg PO at bedtime; may increase to 10 mg if inadequate (1) ·
500 mg PO every 6 hours, or 250 mg every 6 hours for mild infections (1) ·
Allergy: 4 mg PO TID. Serotonin syndrome: 12 mg loading dose PO or by nasogastric tube, then 2 mg every 2 hours until clinical improvement. Appetite stimulation: 2-4 mg PO TID-QID (1) ·
Anxiety: 0.5-1 mg PO BID-TID. Insomnia: 1-2 mg PO at bedtime. Status epilepticus: 4 mg IV (adult), repeat after 5-10 minutes if needed. Acute agitation: 1-2 mg IM (1) ·
Oral 300-450 mg PO QID; IV 600-900 mg q8h; topical 1% solution/gel BID; vaginal 100 mg ovule × 3 days or 2% cream × 7 days (1)
preparations:
25 mg, 50 mg tablets (1) ·
250 mg, 500 mg tablets; 125 mg/5 mL, 250 mg/5 mL suspension (1) ·
250 mg, 500 mg, 750 mg capsules; 250 mg/5 mL, 125 mg/5 mL suspension; tablets (1) ·
250, 500 mg base or stearate tablets; ER tablets; ethyl succinate 200 mg/5 mL suspension; 500 mg, 1 g IV (lactobionate); 2% topical solution/gel; 0.5% ophthalmic ointment (1) ·
5 mg, 10 mg tablets (1) ·
5 mg, 10 mg, 15 mg, 20 mg tablets (1) ·
5, 10, 20, 100 mg tablets; 10 mg/mL IV (1) ·
75, 150, 300 mg capsules; 75 mg/5 mL solution; 150 mg/mL IV; 1% topical; 2% vaginal cream (1) ·
95 mg (OTC), 99.5 mg, 100 mg, 200 mg tablets (1) ·
Tablets 0.5, 1, 2 mg; oral concentrate 2 mg/mL; injection 2 mg/mL and 4 mg/mL; Loreev XR capsules 1, 2, 3 mg (1) ·
Tablets 4 mg; oral syrup 2 mg/5 mL (1)
fda max:
10 mg/d (1) ·
10 mg/day (anxiety, oral) (1) ·
2 g/d typical (1) ·
20 mg/d (1) ·
200 mg/d typical practical ceiling (1) ·
32 mg/day adult; weight-based pediatric ceiling (1) ·
4 g/d (1) ·
4 g/d (rarely tolerated due to GI effects) (1) ·
4.8 g/d (IV severe infection) (1) ·
50 mg/d (1) ·
Limit to 48 hours of use to avoid hemolysis and methemoglobinemia (1)
routes:
onset:
duration: (Click arrow to add another value)
halflife:
12-15 hours (intermediate); '''no active metabolites''' (key clinical feature)'"`UNIQ--ref-00000023-QINU`"' (1) ·
3-4 hours (similar between PO and IV due to high oral bioavailability)'"`UNIQ--ref-00000B46-QINU`"' (1) ·
8-16 hours'"`UNIQ--ref-0000001E-QINU`"' (1) ·
~1 hour'"`UNIQ--ref-000004F2-QINU`"' (1) ·
~1.5-2 hours'"`UNIQ--ref-00000D3E-QINU`"' (1) ·
~12 hours (1) ·
~17-19 hours (longer than daridorexant) (1) ·
~2.5-3 hours'"`UNIQ--ref-00001442-QINU`"' (1) ·
~30-60 minutes'"`UNIQ--ref-00000E76-QINU`"' (1) ·
~7-10 hours (variable; longer in renal impairment)'"`UNIQ--ref-00000FB4-QINU`"' (1) ·
~8 hours (shorter than suvorexant and lemborexant) (1)
bioavailability:
90% (oral; food delays but does not reduce absorption)'"`UNIQ--ref-000004F3-QINU`"' (1) ·
High (oral)'"`UNIQ--ref-00000FB5-QINU`"' (1) ·
~30-65% (oral; acid-labile, hence enteric-coated formulations; food affects absorption variably)'"`UNIQ--ref-00000D3F-QINU`"' (1) ·
~44% (1) ·
~60% (oral; phenoxymethyl modification makes it acid-stable, unlike penicillin G which is destroyed by gastric acid)'"`UNIQ--ref-00000E77-QINU`"' (1) ·
~62% (1) ·
~80% (oral; predictable absorption — a substantive practical advantage over furosemide whose oral absorption is 10-100% variable)'"`UNIQ--ref-00000B47-QINU`"' (1) ·
~82% (1) ·
~90% (oral)'"`UNIQ--ref-00000024-QINU`"' (1) ·
~90% (oral)'"`UNIQ--ref-00001443-QINU`"' (1) ·
~95% (oral)'"`UNIQ--ref-0000001F-QINU`"' (1)
pregnancy:
Avoid where possible; class concerns as for other loop diuretics.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; commonly used in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Limited data; avoid (3) ·
Limited data; not first-line in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; older agent with substantial use experience.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Some signal for cleft lip/palate with first-trimester exposure (debated); neonatal sedation and withdrawal with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
OTC (lower doses) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US (1) ·
OTC (ophthalmic ointment) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) ·
Rx, Schedule IV (US) (3) ·
[[USLegal:Prescription only|Rx-only]] in US (4) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for Clostridioides difficile colitis (one of the most C. difficile-inducing antibiotic classes)'"`UNIQ--ref-00001444-QINU`"' (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US. Carries the benzodiazepine class '''Boxed Warning''' for risk of fatal respiratory depression, coma, and death when combined with opioids'"`UNIQ--ref-00000025-QINU`"' (1)
Showing below up to 11 results in range #1 to #11.